Please use this identifier to cite or link to this item:
Title: SEOM clinical guideline for the management of malignant melanoma (2017).
Authors: Berrocal, A
Arance, A
Castellon, V E
de la Cruz, L
Espinosa, E
Cao, M G
Larriba, J L G
Márquez-Rodas, I
Soria, A
Algarra, S M
Keywords: Adjuvant;B-RAF;Immunotherapy;Melanoma;Metastatic
metadata.dc.subject.mesh: Combined Modality Therapy
Issue Date: 7-Nov-2017
Abstract: All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.
metadata.dc.identifier.doi: 10.1007/s12094-017-1768-1
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5785602.pdf351,8 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons